Rajasthan Orders Recall of 7 Drug Batches After NSQ Findings

Rajasthan's drug regulatory authority has declared seven drug batches Not of Standard Quality (NSQ) and ordered an immediate recall, invoking enforcement powers under the Drugs and Cosmetics Act, 1940. The action targets widely used antimicrobials and antiparasitics including Cefixime, Albendazole, and Ciprofloxacin, placing batch release protocols and distributor accountability under direct scrutiny across the state's pharmaceutical supply chain.

The Commissioner's office has directed private hospitals, medical colleges, pharmacies, and distributors to cease distribution and use of the flagged batches immediately. Enforcement action under the Drugs and Cosmetics Act and its associated provisions is underway. For QA directors and plant heads supplying to Rajasthan, the recall signals that state-level inspectorates are prepared to act swiftly when batch quality data raises red flags, independent of central regulatory timelines.

The inclusion of high-volume generics such as Ciprofloxacin and Cefixime in the NSQ list carries supply continuity implications for public health facilities and retail pharmacies alike. Distributors holding affected stock face immediate compliance obligations, and manufacturers whose batches are implicated will need to initiate root cause analysis aligned with ICH Q10 quality system principles and 21 CFR Part 211 equivalent GMP standards to satisfy regulatory scrutiny.

Source: This report is based on coverage published by Pharmaceutical Industry News on 26 April 2026. The source article contains limited technical detail; claims are confined strictly to information present in the original reporting.